Inventor · disambiguated record
Michael Eck
Also filed as: ECK MICHAEL · ECK MICHAEL J
13 granted patents·17 pending applications·41 citations·filing 2004–2025
88Inventor score
Files withDANA FARBER CANCER INST INC22LIFE TECHNOLOGIES CORP4ECK MICHAEL1ECK MICHAEL J1GRAY NATHANAEL S1
Top patents by PatentIndex Score
30 records- 0188US9908884B2EGFR inhibitors and methods of treating disordersGRAY NATHANAEL S·Filed 2010·Granted Mar 6, 2018·12 cites·5 claims
- 0286US10450310B2Bifunctional molecules for degradation of EGFR and methods of useDANA FARBER CANCER INST INC·Filed 2018·Granted Oct 22, 2019·5 cites·18 claims
- 0380US8361735B2Interference control panel for evaluation of analytical assays for samples derived from bloodLIFE TECHNOLOGIES CORP·Filed 2011·Granted Jan 29, 2013·1 cites·11 claims
- 0480US8097461B2Interference control panel for evaluation of analytical assays for samples derived from bloodECK MICHAEL J·Filed 2007·Granted Jan 17, 2012·3 cites·26 claims
- 0579US10836722B2Inhibitors of EGFR and methods of use thereofDANA FARBER CANCER INST INC·Filed 2019·Granted Nov 17, 2020·1 cites·18 claims
- 0678US10385019B2Inhibitors of EGFR and methods of use thereofDANA FARBER CANCER INST INC·Filed 2016·Granted Aug 20, 2019·2 cites·21 claims
- 0775US2025340534A1Allosteric egfr inhibitors and methods of use thereofDANA FARBER CANCER INST INC·Filed 2025·Application pending·0 cites
- 0875US2025340535A1Allosteric egfr inhibitors and methods of use thereofDANA FARBER CANCER INST INC·Filed 2025·Application pending·0 cites
- 0972US12391671B2Allosteric EGFR inhibitors and methods of use thereofDANA FARBER CANCER INST INC·Filed 2022·Granted Aug 19, 2025·0 cites·29 claims
- 1071US2014323334A1Interference Control Panel for Evaluation of Analytical Assays For Samples Derived from BloodLIFE TECHNOLOGIES CORP·Filed 2014·Application pending·0 cites
- 1170US7290773B2Glide sport article, especially ice skateECK MICHAEL·Filed 2004·Granted Nov 6, 2007·17 cites·9 claims
- 1268US2022017510A1Bifunctional molecules for degradation of egfr and methods of useDANA FARBER CANCER INST INC·Filed 2021·Application pending·0 cites
- 1367US11161842B2Bifunctional molecules for degradation of EGFR and methods of useDANA FARBER CANCER INST INC·Filed 2019·Granted Nov 2, 2021·0 cites·19 claims
- 1467US2013109026A1Interference control panel for evaluation of analytical assays for samples derived from bloodLIFE TECHNOLOGIES CORP·Filed 2012·Application pending·0 cites
- 1566US2021094913A1Inhibitors of egfr and methods of use thereofDANA FARBER CANCER INST INC·Filed 2020·Application pending·0 cites
- 1663US11945816B2Inhibitors of EGFR and/or HER2 and methods of useDANA FARBER CANCER INST INC·Filed 2021·Granted Apr 2, 2024·0 cites·16 claims
- 1761US2015252442A1Interference Control Panel for Evaluation of Analytical Assays for Samples Derived from BloodLIFE TECHNOLOGIES CORP·Filed 2015·Application pending·0 cites
- 1860US2023406838A1Mutant selective egfr inhibitors and methods of use thereofDANA FARBER CANCER INST INC·Filed 2023·Application pending·0 cites
- 1955US11186574B2Inhibitors of EGFR and/or HER2 and methods of useDANA FARBER CANCER INST INC·Filed 2018·Granted Nov 30, 2021·0 cites·20 claims
- 2050US2019040065A1EGFR Inhibitors and Methods of Treating DisordersDANA FARBER CANCER INST INC·Filed 2018·Application pending·0 cites
- 2149US12377080B2Allosteric EGFR inhibitors and methods of use thereofDANA FARBER CANCER INST INC·Filed 2020·Granted Aug 5, 2025·0 cites·20 claims
- 2248US2020377501A1Degraders of egfr and methods of use thereofDANA FARBER CANCER INST INC·Filed 2019·Application pending·0 cites
- 2346US2022233545A1Allosteric egfr inhibitors and methods of use thereofDANA FARBER CANCER INST INC·Filed 2020·Application pending·0 cites
- 2443US11584746B2Inhibitors of EGFR and methods of use thereofDANA FARBER CANCER INST INC·Filed 2019·Granted Feb 21, 2023·0 cites·22 claims
- 2543US2021085688A1Pharmaceutical combinations of egfr inhibitors and methods of use thereofDANA FARBER CANCER INST INC·Filed 2019·Application pending·0 cites
- 2642US2020375999A1Pharmaceutical combinations of egfr inhibitors and methods of use thereofDANA FARBER CANCER INST INC·Filed 2019·Application pending·0 cites
- 2742US2021077469A1Pharmaceutical combinations of egfr inhibitors and methods of use thereofDANA FARBER CANCER INST INC·Filed 2019·Application pending·0 cites
- 2842US2017304033A1Form for producing a pre-molded prosthesis-base blankHERAEUS KULZER GMBH·Filed 2015·Application pending·0 cites
- 2941US2020390783A1Inhibitors of egfr and methods of use thereofDANA FARBER CANCER INST INC·Filed 2019·Application pending·0 cites
- 3041US2020377477A1Degraders of egfr and methods of use thereofDANA FARBER CANCER INST INC·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Michael Eck files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →